S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.15 (+2.09%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.68 (+2.51%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.13 (+0.77%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.68 (+2.79%)
PRI   125.80 (+0.00%)
BAC   31.43 (+0.74%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.15 (+2.09%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.68 (+2.51%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.13 (+0.77%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.68 (+2.79%)
PRI   125.80 (+0.00%)
BAC   31.43 (+0.74%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
Log in

CombiMatrix Stock Price, News & Analysis (NASDAQ:CBMX)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume119,111 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. It performs genetic testing utilizing a range of cytogenomic techniques, including chromosomal microarray analysis, fluorescence in situ hybridization and karyotyping. Its prenatal and postnatal microarray focuses on diagnosing genomic syndromes associated with intellectual disability, developmental delays, congenital anomalies, dysmorphic features and autism spectrum disorders. It develops and markets its molecular testing services in approximately four markets, such as in vitro fertilization (IVF), miscarriage analysis (products of conception analysis), prenatal genetics and postnatal developmental disorders.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:CBMX
CUSIPN/A
Phone+1-949-7530624

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive CBMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CBMX and its competitors with MarketBeat's FREE daily newsletter.


CombiMatrix (NASDAQ:CBMX) Frequently Asked Questions

What is CombiMatrix's stock symbol?

CombiMatrix trades on the NASDAQ under the ticker symbol "CBMX."

When did CombiMatrix's stock split? How did CombiMatrix's stock split work?

CombiMatrix's stock reverse split on the morning of Monday, February 1st 2016. The 1-15 reverse split was announced on Wednesday, January 27th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 29th 2016. An investor that had 100 shares of CombiMatrix stock prior to the reverse split would have 7 shares after the split.

How were CombiMatrix's earnings last quarter?

CombiMatrix Corp (NASDAQ:CBMX) posted its quarterly earnings results on Monday, November, 6th. The medical research company reported ($0.08) EPS for the quarter, beating the Zacks' consensus estimate of ($0.11) by $0.03. The medical research company had revenue of $4.01 million for the quarter, compared to the consensus estimate of $4.19 million. During the same quarter in the previous year, the business posted ($0.38) EPS. View CombiMatrix's Earnings History.

Has CombiMatrix been receiving favorable news coverage?

Press coverage about CBMX stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CombiMatrix earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for CombiMatrix.

What other stocks do shareholders of CombiMatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CombiMatrix investors own include Vermillion (VRML), NovaBay Pharmaceuticals (NBY), Charter Communications (CHTR), InspireMD (NSPR), CorMedix (CRMD), BIOLASE (BIOL), Glu Mobile (GLUU), GTX (GTXI), Microbot Medical (MBOT) and Rigel Pharmaceuticals (RIGL).

Who are CombiMatrix's key executives?

CombiMatrix's management team includes the folowing people:
  • Robert Judd Jessup, Chairman of the Board (Age 68)
  • Mark McDonough, President, Chief Executive Officer, Director (Age 46)
  • Scott R. Burell, Chief Financial Officer, Treasurer, Secretary (Age 52)
  • Dirk van den Boom Ph.D., Director (Age 47)
  • Robert E. Hoffman, Independent Director (Age 51)
  • Jeremy M. Jones, Independent Director (Age 75)
  • Lale White, Independent Director (Age 60)

What is CombiMatrix's official website?

The official website for CombiMatrix is http://combimatrix.com/.

How can I contact CombiMatrix?

CombiMatrix's mailing address is 310 Goddard Ste 150, IRVINE, CA 92618-4617, United States. The medical research company can be reached via phone at +1-949-7530624.


MarketBeat Community Rating for CombiMatrix (NASDAQ CBMX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  163
MarketBeat's community ratings are surveys of what our community members think about CombiMatrix and other stocks. Vote "Outperform" if you believe CBMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel